Archived Newsletters

  1. 11.02.22 -- Stand Shoulder-To-Shoulder With Your CDMO 11/2/2022
    11/02/22 Outsourced Pharma Newsletter
  2. 11.01.22 -- How To De-Risk Your Biologic's Development And Manufacturing Process 11/1/2022

    11/01/22 Outsourced Pharma Newsletter

  3. 11.01.22 -- Are your components tested to the Max? 11/1/2022

    11/01/22 Outsourced Pharma Newsletter

  4. 10.31.22 -- Have CDMO Selection Criteria Changed Over The Past Five Years? 10/31/2022

    10/31/22 Outsourced Pharma Newsletter

  5. 10.31.22 -- Assessing mRNA Vaccine Quality 10/31/2022
    10/31/22 Outsourced Pharma Newsletter
  6. 10.28.22 -- Discover CDMOs With A Focus On Cell & Gene Therapy 10/28/2022
    10/28/22 Outsourced Pharma Newsletter
  7. 10.27.22 -- From Cells To Capsid Separation: A Scalable rAAV Process 10/27/2022

    10/27/22 Outsourced Pharma Newsletter

  8. 10.26.22 -- Innovative Solutions For mRNA, Bispecific Antibodies, Viral Vectors, And More 10/26/2022

    10/26/22 Outsourced Pharma Newsletter

  9. 10.26.22 -- CDMOs Need To Digitize Now 10/26/2022
    10/26/22 Outsourced Pharma Newsletter
  10. 10.24.22 -- Mitigating Common Pitfalls In Early Drug Development 10/24/2022

    10/24/22 Outsourced Pharma Newsletter